RareCyte, Inc., a Seattle, WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing.
Arboretum Ventures led the financing joined by other new investors F-Prime Capital, Logos Capital, and Agilent Technologies. Existing investors participating in the financing included HealthQuest Capital, 5AM Ventures, and Company founder Ron Seubert. Jan Garfinkle, Arboretum Managing Partner, joined the RareCyte Board of Directors along with Robert Weisskoff, Ph.D., Partner at F-Prime Capital.
The company intends to use the funds to drive the commercialization and applications for its new Orion spatial biology platform and further global expansion for its portfolio of instruments and consumables.
Led by Joe Victor, President and CEO, RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The company has deep experience in developing advanced precision life science systems used in labs worldwide.